BEGIN:VCALENDAR PRODID:-//github.com/ical-org/ical.net//NONSGML ical.net 5.1.4//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:  We will be welcoming Associate Professor Danielle Stanisic t o our club to update us on the Phase I clinical trial of the field deploya ble PlasProtecT malaria vaccine.   ***After being carefully produced in the GMP-compliant facility at Griffith University\, the vaccine has passed a crucial sterility test\, building on its success in toxicological testi ng last year. With these milestones achieved\, the team is now ready to pr epare the Investigational Brochure and Clinical Trial Protocol\, which wil l be submitted for Ethics approval to launch the trial in Q3 this year. Ac cording to the most recent global data for 2023\, there were 263 million m alaria cases\, a worrying increase from the previous year’s 249 million cases. While the estimated death toll of 597\,000 is slightly lower than t he 608\,000 deaths in 2022\, the numbers remain unacceptably high. The WHO reports that humanitarian emergencies—caused by conflict\, violence\, a nd natural disasters—disproportionately affected malaria-endemic populat ions in 2023. Global warming\, coupled with rising humidity levels\, has e merged as a major driver in the malaria death rate. On top of that\, the s pread of drug resistance in both Africa and Asia\, along with rising mosqu ito resistance to insecticides\, threatens to derail progress. Alarmingly\ , the highly infectious Asian mosquito\, Anopheles stephensi\, has now inf iltrated the Horn of Africa\, fuelling new malaria cases in urban centers. If this mosquito spreads further across the continent\, the consequences could be catastrophic. *** Extract from the latest District 9640 MALARIA V ACCINE PROJECT newsletter. Please also see attached a copy of the newslett er for your perusal. DTEND:20250403T223000Z DTSTAMP:20260417T031256Z DTSTART:20250403T213000Z LOCATION:Southport Yacht Club 1 Macarthur PDE Main Beach\, VIC Australia 4 217 SEQUENCE:1 STATUS:CONFIRMED SUMMARY:Guest Speaker Associate Professor Danielle Stanisic\, PhD\, Researc h Leader and Principal Research Fellow\,\, Institute for Biomedicine and G lycomics UID:1f812b42-4fa8-47c0-9bd3-34bbd716a7ec-638793126000000000 X-ALT-DESC;FMTTYPE=text/html:
\n
 \;
\n\n
We will be w elcoming Associate Professor Danielle Stanisic to our club to update us on the Phase I clinical trial of the field deployable PlasProtecT malaria va ccine. \; \;
\n\n
***After being carefully produced in th e GMP-compliant facility at Griffith University\, the vaccine has passed a crucial sterility test\, building on its success in toxicological testing last year. With these milestones achieved\, the team is now ready to prep are the Investigational Brochure and Clinical Trial Protocol\, which will be submitted for Ethics approval to launch the trial in Q3 this year.
\nAccording to the most recent global data for 2023\, there were 263 mill ion malaria cases\, a worrying increase from the previous year’s 249 mil lion cases. While the estimated death toll of 597\,000 is slightly lower t han the 608\,000 deaths in 2022\, the numbers remain unacceptably high.
\nThe WHO reports that humanitarian emergencies—caused by conflict\, violence\, and natural disasters—disproportionately affected malaria-end emic populations in 2023. Global warming\, coupled with rising humidity le vels\, has emerged as a major driver in the malaria death rate. On top of that\, the spread of drug resistance in both Africa and Asia\, along with rising mosquito resistance to insecticides\, threatens to derail progress. Alarmingly\, the highly infectious Asian mosquito\, Anopheles stephensi\, has now infiltrated the Horn of Africa\, fuelling new malaria cases in ur ban centers. If this mosquito spreads further across the continent\, the c onsequences could be catastrophic.
\n\n
*** Extract from the late st District 9640 MALARIA VACCINE PROJECT newsletter. Please also see attac hed a copy of the newsletter for your perusal.
\n
\n END:VEVENT END:VCALENDAR